BACKGROUND: Studies comparing survival of adolescent and young adult (AYA) patients to that of younger patients with newly diagnosed acute myeloid leukemia (AML) have yielded conflicting results. In order to more accurately characterize relative survival and other outcomes of AYA patients, a cross-study analysis was conducted using data from recent trials conducted by the Children's Cancer Group (CCG) and Children's Oncology Group (COG). METHODS: Data were combined from the CCG-2891, CCG-2941, CCG-2961, and AAML03P1 trials. The data set included 1840 patients, comprising 238 AYA and 1602 younger patients. RESULTS: Overall survival was not significantly different in the 2 groups (AYA, 49% ± 7% versus younger, 54% ± 3% (± 2 standard errors), P = .058). Relapse was lower in AYA patients (30% ± 7% versus 41% ± 3%, P = .002), but treatment-related mortality (TRM) was higher (25% ± 6% versus 12% ± 2%, P < .001). After adjustment for other factors, older age remained strongly associated with TRM (hazard ratio = 2.30, 95% CI = 1.59-3.33, P < .001). Infection accounted for the excess TRM in AYA patients. CONCLUSIONS: Survival in AYA and younger patients with newly diagnosed AML is similar; however, older patients are at higher risk for TRM. More effective strategies for preventing mortality from infection in AYA patients are needed.
BACKGROUND: Studies comparing survival of adolescent and young adult (AYA) patients to that of younger patients with newly diagnosed acute myeloid leukemia (AML) have yielded conflicting results. In order to more accurately characterize relative survival and other outcomes of AYApatients, a cross-study analysis was conducted using data from recent trials conducted by the Children's Cancer Group (CCG) and Children's Oncology Group (COG). METHODS: Data were combined from the CCG-2891, CCG-2941, CCG-2961, and AAML03P1 trials. The data set included 1840 patients, comprising 238 AYA and 1602 younger patients. RESULTS: Overall survival was not significantly different in the 2 groups (AYA, 49% ± 7% versus younger, 54% ± 3% (± 2 standard errors), P = .058). Relapse was lower in AYApatients (30% ± 7% versus 41% ± 3%, P = .002), but treatment-related mortality (TRM) was higher (25% ± 6% versus 12% ± 2%, P < .001). After adjustment for other factors, older age remained strongly associated with TRM (hazard ratio = 2.30, 95% CI = 1.59-3.33, P < .001). Infection accounted for the excess TRM in AYApatients. CONCLUSIONS: Survival in AYA and younger patients with newly diagnosed AML is similar; however, older patients are at higher risk for TRM. More effective strategies for preventing mortality from infection in AYApatients are needed.
Authors: Soheil Meshinchi; Todd A Alonzo; Derek L Stirewalt; Michel Zwaan; Martin Zimmerman; Dirk Reinhardt; Gertjan J L Kaspers; Nyla A Heerema; Robert Gerbing; Beverly J Lange; Jerald P Radich Journal: Blood Date: 2006-08-15 Impact factor: 22.113
Authors: David Becton; Gary V Dahl; Yaddanapudi Ravindranath; Myron N Chang; Fred G Behm; Susana C Raimondi; David R Head; Kimo C Stine; Norman J Lacayo; Branimir Ivan Sikic; Robert J Arceci; Howard Weinstein Journal: Blood Date: 2005-10-27 Impact factor: 22.113
Authors: Todd M Cooper; Janet Franklin; Robert B Gerbing; Todd A Alonzo; Craig Hurwitz; Susana C Raimondi; Betsy Hirsch; Franklin O Smith; Prasad Mathew; Robert J Arceci; James Feusner; Robert Iannone; Robert S Lavey; Soheil Meshinchi; Alan Gamis Journal: Cancer Date: 2011-07-15 Impact factor: 6.860
Authors: W G Woods; S Neudorf; S Gold; J Sanders; J D Buckley; D R Barnard; K Dusenbery; J DeSwarte; D C Arthur; B J Lange; N L Kobrinsky Journal: Blood Date: 2001-01-01 Impact factor: 22.113
Authors: Ursula Creutzig; Martin Zimmermann; Thomas Lehrnbecher; Norbert Graf; Johann Hermann; Charlotte M Niemeyer; Alfred Reiter; Jörg Ritter; Michael Dworzak; Jan Stary; Dirk Reinhardt Journal: J Clin Oncol Date: 2006-09-20 Impact factor: 44.544
Authors: Paul C Rogers; Steven J Melnick; Elena J Ladas; Jacqueline Halton; Jacques Baillargeon; Nancy Sacks Journal: Pediatr Blood Cancer Date: 2008-02 Impact factor: 3.167
Authors: Patrick Brown; Emily McIntyre; Rachel Rau; Soheil Meshinchi; Norman Lacayo; Gary Dahl; Todd A Alonzo; Myron Chang; Robert J Arceci; Donald Small Journal: Blood Date: 2007-04-17 Impact factor: 22.113
Authors: Elizabeth M Jaffee; Chi Van Dang; David B Agus; Brian M Alexander; Kenneth C Anderson; Alan Ashworth; Anna D Barker; Roshan Bastani; Sangeeta Bhatia; Jeffrey A Bluestone; Otis Brawley; Atul J Butte; Daniel G Coit; Nancy E Davidson; Mark Davis; Ronald A DePinho; Robert B Diasio; Giulio Draetta; A Lindsay Frazier; Andrew Futreal; Sam S Gambhir; Patricia A Ganz; Levi Garraway; Stanton Gerson; Sumit Gupta; James Heath; Ruth I Hoffman; Cliff Hudis; Chanita Hughes-Halbert; Ramy Ibrahim; Hossein Jadvar; Brian Kavanagh; Rick Kittles; Quynh-Thu Le; Scott M Lippman; David Mankoff; Elaine R Mardis; Deborah K Mayer; Kelly McMasters; Neal J Meropol; Beverly Mitchell; Peter Naredi; Dean Ornish; Timothy M Pawlik; Jeffrey Peppercorn; Martin G Pomper; Derek Raghavan; Christine Ritchie; Sally W Schwarz; Richard Sullivan; Richard Wahl; Jedd D Wolchok; Sandra L Wong; Alfred Yung Journal: Lancet Oncol Date: 2017-10-31 Impact factor: 41.316
Authors: Ditte J A Løhmann; Jonas Abrahamsson; Shau-Yin Ha; Ólafur G Jónsson; Minna Koskenvuo; Birgitte Lausen; Josefine Palle; Bernward Zeller; Henrik Hasle Journal: Haematologica Date: 2016-07-28 Impact factor: 9.941
Authors: Ursula Creutzig; Matthew A Kutny; Ronald Barr; Richard F Schlenk; Raul C Ribeiro Journal: Pediatr Blood Cancer Date: 2018-04-18 Impact factor: 3.167
Authors: Aaron R Weiss; Brandon Hayes-Lattin; Matthew A Kutny; Wendy Stock; Kristin Stegenga; David R Freyer Journal: Semin Oncol Nurs Date: 2015-05-07 Impact factor: 2.315